The SARS-Cov-2 pandemic in 2020 has caused oncology teams around the world to adapt their practice in the aim of protecting patients . Early evidence from China indicated that patients with cancer, and particularly those who had recently received chemotherapy or surgery, were at increased risk of adverse outcomes following SARS-Cov-2 infection . Many registries of cancer patients infected with SARS-Cov-2 emerged during the first wave . We collate the evidence from these national and international studies and focus on the risk factors for patients with solid cancers and the contribution of systemic anti-cancer treatments (SACT-chemotherapy, immunotherapy, targeted and hormone therapy) to outcomes following SARS-Cov-2 infection . Patients with cancer infected with SARS-Cov-2 have a higher probability of death compared with patients without cancer . Common risk factors for mortality following COVID-19 include age, male sex, smoking history, number of comorbidities and poor performance status . Oncological features that may predict for worse outcomes include tumour stage, disease trajectory and lung cancer . Most studies did not identify an association between SACT and adverse outcomes . Recent data suggest that the timing of receipt of SACT may be associated with risk of mortality . Ongoing recruitment to these registries will enable us to provide evidence-based care.